Matching Placebo tablets without active substance, BIIB122 clinical trials

283PD201 (LUMA): A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease

This study is looking into a new medication called BIIB122 for Parkinson's disease. We want to see if it helps slow down the disease's effects on movement and daily activities, compared to a dummy pill. It's an important step in finding new ways to manage Parkinson's.